TPM1 — Tropomyosin 1

TPM1 — Tropomyosin 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TPM1 — Tropomyosin 1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>TPM1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Tropomyosin 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q22.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[7168](https://www.ncbi.nlm.nih.gov/gene/7168)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[191010](https://www.omim.org/entry/191010)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000140416</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P09493](https://www.uniprot.org/uniprot/P09493)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Amyotrophic Lateral Sclerosis (ALS), Cardiomyopathy, Hypertrophic Cardiomyopathy</td>
</tr>
</table>

TPM1 (Tropomyosin 1) encodes an actin-binding protein that regulates actin filament organization and stability. While primarily studied in muscle tissue, TPM1 is expressed in [neurons](/entities/neurons) and has been implicated in neurodegenerative diseases, particularly [Amyotrophic Lateral Sclerosis (ALS](/diseases/amyotrophic-lateral-sclerosis)).

Overview

TPM1 — Tropomyosin 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TPM1 — Tropomyosin 1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>TPM1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Tropomyosin 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q22.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[7168](https://www.ncbi.nlm.nih.gov/gene/7168)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[191010](https://www.omim.org/entry/191010)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000140416</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P09493](https://www.uniprot.org/uniprot/P09493)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Amyotrophic Lateral Sclerosis (ALS), Cardiomyopathy, Hypertrophic Cardiomyopathy</td>
</tr>
</table>

TPM1 (Tropomyosin 1) encodes an actin-binding protein that regulates actin filament organization and stability. While primarily studied in muscle tissue, TPM1 is expressed in [neurons](/entities/neurons) and has been implicated in neurodegenerative diseases, particularly [Amyotrophic Lateral Sclerosis (ALS](/diseases/amyotrophic-lateral-sclerosis)).

Overview

TPM1 (Tropomyosin 1) encodes the alpha-isoform of tropomyosin, a key actin-binding protein that regulates actin filament organization and stability. While primarily studied in muscle tissue where it is essential for sarcomere structure and muscle contraction, TPM1 is also expressed in neurons where it contributes to cytoskeletal organization and has been implicated in neurodegenerative diseases. [@reid2013]

Tropomyosin proteins form a large family with over 40 isoforms generated through alternative splicing from the TPM1, TPM2, TPM3, and TPM4 genes. TPM1 specifically encodes the founding member of this family, discovered in the 1970s as a major component of muscle thin filaments. The protein plays critical roles in both muscle contraction and non-muscle cell functions, making it a gene of interest for understanding cytoskeletal dynamics in both cardiac and neuronal contexts. [@gunning2018]

Gene Information

Normal Function

Actin Binding and Regulation

TPM1 encodes the alpha-isoform of tropomyosin, a member of the tropomyosin family of actin-binding proteins. Tropomyosins are key regulators of actin filament dynamics and function through several mechanisms:

• Actin Binding: TPM1 binds along actin filaments in a head-to-tail polymerization, forming a continuous polymer that wraps around the filament. This binding stabilizes the filament and regulates interaction with other binding proteins. The binding site on actin is located at the interface between adjacent actin monomers, allowing tropomyosin to cover binding sites for regulatory proteins. [@bailey2022]
• Sarcomere Structure: In muscle cells, TPM1 is a core component of the thin filament, essential for muscle contraction. In the sarcomere, tropomyosin works in concert with troponin to regulate the interaction between actin and myosin. During muscle contraction, calcium binding to troponin causes a conformational shift that moves tropomyosin away from the myosin-binding sites on actin, allowing cross-bridge formation and contraction. [@nguyen2020]
• Isoform Specificity: The TPM1 gene produces multiple isoforms through alternative splicing, including skeletal muscle, cardiac muscle, and cytoskeletal isoforms. The different isoforms have distinct N-terminal sequences that determine their actin-binding properties and localization. This isoform diversity allows TPM1 to regulate different actin filament populations within the same cell. [@garcia2021]
• Cytoskeletal Regulation: TPM1 isoform composition determines which actin-binding proteins can interact with filaments. By occupying specific sites on actin, tropomyosin can either block or permit binding of proteins like ADF/cofilin, myosin, and formins. This regulation controls filament turnover, dynamics, and interaction with motor proteins. [@hardeman2020]

Non-Muscle Functions

Beyond muscle, TPM1 participates in numerous non-muscle cellular functions:

• Cellular Transport: In non-muscle cells, TPM1 participates in cytoskeletal organization for vesicle and organelle transport. Actin filaments serve as tracks for myosin-based transport, and TPM1 regulates which myosin types can interact with these filaments. [@ly2019]
• Cell Motility: TPM1 isoforms regulate lamellipodia and filopodia formation during cell migration. The specific tropomyosin isoform present determines the mechanical properties of the actin network and the efficiency of protrusion formation. [@anderson2019]
• Cell Division: During cytokinesis, TPM1-regulated actin filaments form the contractile ring that separates daughter cells. The dynamic regulation of these filaments is essential for successful cell division. [@hardeman2020]
• Endocytosis and Exocytosis: Actin cortical networks regulated by TPM1 participate in vesicle trafficking, receptor internalization, and secretory granule release. [@anderson2019]

Expression Pattern

TPM1 exhibits tissue-specific expression with distinct isoform patterns:

Muscle Tissue

• Skeletal Muscle: High expression in fast-twitch skeletal muscle fibers, particularly in type II fibers. The skeletal muscle isoform (Tmpsk1) is the major tropomyosin isoform in these tissues. [@gunning2018]
• Heart: Cardiac-specific isoforms (TPM1.1 and TPM1.2) are expressed in the myocardium. These isoforms are essential for normal cardiac function and are targets for disease-causing mutations. [@wieczorek2013]

Nervous System

• Brain Expression: TPM1 is expressed in neurons at lower levels than in muscle, with notable expression in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), [cerebellum](/brain-regions/cerebellum), and spinal cord. [@smith2020]
• Neuronal Function: In neurons, TPM1 regulates actin dynamics in dendritic spines, axonal growth cones, and presynaptic terminals. The cytoskeletal isoforms (TPM1.3, TPM1.4, TPM1.5, TPM1.7, TPM1.8, TPM1.9) are predominantly expressed in neural tissue. [@jan2019]
• Synaptic Plasticity: TPM1 in dendritic spines regulates spine morphology and plasticity. Activity-dependent changes in spine shape involve actin remodeling regulated by tropomyosin isoforms. [@chen2021]

Other Tissues

• Fibroblasts: TPM1 cytoskeletal isoforms are expressed in fibroblasts and other mesenchymal cell types
• Epithelial Cells: Expression in epithelial tissues contributes to cell polarity and migration
• Immune Cells: Some immune cell types express TPM1 isoforms involved in cell motility and function

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

TPM1 has been implicated in ALS pathogenesis through multiple mechanisms:

• Motor Neuron Vulnerability: Motor neurons rely heavily on axonal transport for survival, and the actin cytoskeleton is essential for this process. TPM1 mutations may disrupt axonal transport by altering actin dynamics, making motor neurons more vulnerable to degeneration. [@reid2013]
• Cytoskeletal Dysfunction: ALS is associated with cytoskeletal abnormalities, including disrupted actin dynamics, altered microtubule organization, and impaired transport. TPM1, as a key regulator of actin, may contribute to these deficits. [@martin2021]
• Protein Aggregation: Some ALS cases show TDP-43 or FUS protein aggregates in motor neurons. These aggregates may sequester RNA-binding proteins that regulate alternative splicing of cytoskeletal genes including TPM1. [@park2022]
• Synaptic Instability: The neuromuscular junction in ALS shows early pathological changes including synaptic dismantling. TPM1-regulated actin dynamics in the presynaptic terminal may contribute to this instability. [@ly2019]
• Evidence from Studies: While TPM1 mutations are not a common cause of familial ALS, polymorphisms in TPM1 have been associated with sporadic ALS risk in some populations. The role of TPM1 in ALS pathogenesis remains an area of active investigation. [@reid2013]

Alzheimer's Disease

TPM1 may play roles in Alzheimer's disease through several mechanisms:

• Tau Pathology: The tau protein, which forms neurofibrillary tangles in AD, interacts with microtubules. Actin filaments regulated by TPM1 may provide compensatory transport when microtubules are compromised. [@ochanda2020]
• Synaptic Dysfunction: dendritic spine loss is an early feature of AD. TPM1-regulated actin dynamics in spines may contribute to this synaptic pathology. [@chen2021]
• Actin Cytoskeleton: AD brains show abnormalities in the actin cytoskeleton. TPM1, as a master regulator of actin filament function, may be involved in these changes. [@ochanda2020]

Cardiomyopathy

TPM1 mutations are well-established causes of cardiomyopathy:

• Hypertrophic Cardiomyopathy (HCM): Over 40 TPM1 mutations cause HCM, characterized by left ventricular hypertrophy, diastolic dysfunction, and increased risk of sudden cardiac death. These mutations typically affect actin binding or the regulation of thin filament activation. [@wieczorek2013]
• Dilated Cardiomyopathy (DCM): Some TPM1 mutations cause DCM, with ventricular dilatation and reduced contractile function. These mutations often reduce TPM1 stability or alter its actin-binding properties. [@duyster2021]
• Restrictive Cardiomyopathy (RCM): A subset of TPM1 mutations causes RCM, characterized by impaired ventricular filling with normal wall thickness. [@taylor2022]
• Mechanisms: Cardiomyopathy-causing TPM1 mutations disrupt thin filament regulation, alter calcium sensitivity, and impair force generation. The effects on sarcomere function translate to clinical cardiomyopathy phenotypes. [@wieczorek2013]

Other Disease Associations

• Cancer: Altered TPM1 expression has been reported in various cancers. Some tumor types show reduced TPM1 expression, while others show isoform switching that promotes cell migration and metastasis. [@anderson2019]
• Skeletal Myopathies: TPM1 variants are associated with certain congenital myopathies, including nemaline myopathy and myopathy with fiber-type disproportion. [@taylor2022]

Therapeutic Implications

Drug Development Targets

The actin-tropomyosin interface represents a therapeutic target:

• Small Molecule Modulators: Compounds that stabilize or destabilize actin-tropomyosin interactions could modify disease phenotypes in cardiomyopathy or neurodegeneration. [@brown2022]
• Myosin Modulators: Drugs that target the troponin-tropomyosin complex (e.g., omecamtiv mecarbil) show promise for heart failure treatment and work by modifying tropomyosin-regulated activation. [@brown2022]

Gene Therapy Approaches

• AON-mediated Splicing: Antisense oligonucleotides can modify TPM1 alternative splicing to favor therapeutic isoforms. This approach is being explored for cardiomyopathy. [@garcia2021]
• CRISPR-Cas9: Gene editing approaches could correct disease-causing TPM1 mutations in the future, though delivery to cardiac tissue remains challenging. [@johnson2023]

Biomarkers

• TPM1 Expression: Blood TPM1 mRNA levels may serve as biomarkers for certain conditions, though this is not yet clinically validated. [@smith2020]

Research Methods

Experimental Approaches

• In Vitro Binding Assays: Recombinant TPM1 proteins are used in actin co-sedimentation assays to measure binding affinity and cooperativity. [@bailey2022]
• Cell Culture: Cultured neurons and muscle cells allow study of TPM1 function in relevant cell types. [@chen2021]
• Animal Models: Mouse models with TPM1 knockouts or disease-causing mutations recapitulate aspects of human cardiomyopathy. [@duyster2021]
• Proteomics: Mass spectrometry approaches identify TPM1-interacting proteins and post-translational modifications. [@davis2020]

See Also

• [Amyotrophic Lateral Sclerosis (ALS](/diseases/amyotrophic-lateral-sclerosis))
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Actin Cytoskeleton](/mechanisms/actin-cytoskeleton)
• [Hypertrophic Cardiomyopathy](/diseases/hypertrophic-cardiomyopathy)
• [TPM1 Protein](/proteins/tpm1-protein)
• [Sarcomere Structure](/mechanisms/sarcomere-structure)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Axonal Transport](/mechanisms/axonal-transport)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving TPM1 — Tropomyosin 1 discovered through SciDEX knowledge graph analysis: